| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 01/01/2014 | CN102526055B Application of cyclohexanediamine hypocrelline B in photodynamic anti-tumor medicaments |
| 01/01/2014 | CN102512662B Protein containing 36-83 amino acid motifs in Coxsackie B3virus 2B protein and application thereof |
| 01/01/2014 | CN102512661B Protein containing 1st to 79th sites of amino acid basic sequences in protein 2C of coxsackievirus B3 and application for same |
| 01/01/2014 | CN102512660B Protein containing 51st to 89th sites of amino acid basic sequences in protein 3A of coxsackievirus B3 and application for same |
| 01/01/2014 | CN102477009B Substitutive (S)-benaldehyde sulfonyl pyrrolidine-3-amino derivative, and preparation method and application thereof |
| 01/01/2014 | CN102430054B Applications of traditional Chinese medicinal compound preparation for removing toxicity, resisting cancer, activating blood and dissipating mass |
| 01/01/2014 | CN102408453B Salicylaldehyde Schiff base binuclear cobalt coordination compound and preparation method and application thereof |
| 01/01/2014 | CN102335223B Traditional Chinese medicine for treating human papillomavirus infection symptom as well as preparation method and application thereof |
| 01/01/2014 | CN102227410B Bis [o-(14-benzoylaconine-8-yl)] esters |
| 01/01/2014 | CN102036987B Polysubstituted derivatives of 2-heteroaryl-6-phenyl-imidazo[l,2- a] pyridines, and preparation and therapeutic use thereof |
| 01/01/2014 | CN101760474B EMX2 adenovirus vector and application thereof |
| 01/01/2014 | CN101589024B Novel minor groove binders |
| 01/01/2014 | CN101553500B GnRH peptide derivative (gonadotropin-releasing hormone) |
| 01/01/2014 | CN101502579B Chinese medicinal composition for treating digestive tumor and preparation method thereof |
| 01/01/2014 | CN101396346B 紫杉醇脂质复合物 Paclitaxel-lipid complexes |
| 01/01/2014 | CN101001646B Stabilized synthetic immunogen delivery system |
| 12/31/2013 | US8618276 Distinguishing PCA3 messenger RNA species in benign and malignant prostate tissues |
| 12/31/2013 | US8618146 Epothilone compound formulations |
| 12/31/2013 | US8618141 Aryl ureas with angiogenesis inhibiting activity |
| 12/31/2013 | US8618103 Inhibitors of JAK |
| 12/31/2013 | US8618101 N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline forms and processes |
| 12/31/2013 | US8618097 Pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
| 12/31/2013 | US8618045 Modified human tumor necrosis factor receptor-1 polypeptide or fragment thereof, and method for preparing same |
| 12/31/2013 | US8617822 Method of inhibiting binding or activity of MIF by administering a MIF antagonist |
| 12/31/2013 | US8617598 Pharmaceutical compositions comprising colloidal silicon dioxide |
| 12/31/2013 | US8617540 Combinational chemotherapy treatment |
| 12/31/2013 | CA2775266C Anti-cancer tamoxifen-melatonin hybrid ligand |
| 12/31/2013 | CA2722364C Melanoma antigens |
| 12/31/2013 | CA2636960C Pharmaceutical composition comprising a specific inhibitor of hedgehog/smoothened signaling and a corticosteroid |
| 12/31/2013 | CA2630562C Tricyclic compounds useful as inhibitors of kinases |
| 12/31/2013 | CA2625042C Iontophoretic preparation for treatment of breast cancer and/or mastitis |
| 12/31/2013 | CA2619153C Regulation of protein synthesis by inhibition of eif4e-eif4g interaction |
| 12/31/2013 | CA2608378C New fluorene derivatives, compositions containing the same and use thereof |
| 12/31/2013 | CA2587489C Mediators of hedgehog signaling pathways, compositions and uses related thereto |
| 12/31/2013 | CA2548454C Medicament comprising recombinant antibody against chemokine receptor ccr4 |
| 12/31/2013 | CA2523868C Combinations comprising a protein tyrosine kinase receptor antagonist and a chemotherapeutic or naturally occurring, semi-synthetic of synthetic therapeutic agent for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis |
| 12/31/2013 | CA2523001C Therapeutic use of anti-cs1 antibodies |
| 12/31/2013 | CA2467908C Mfg-e8-l regulates phagocytic removal of apoptotic cells by macrophages |
| 12/27/2013 | WO2013192506A1 Method and composition for alleviating tumor symptoms |
| 12/27/2013 | WO2013192504A1 Novel vista-ig constructs and the use of vista-ig for treatment of autoimmune, allergic and inflammatory disorders |
| 12/27/2013 | WO2013192367A1 Neuroendocrine tumor treatment |
| 12/27/2013 | WO2013192301A1 Imidazo bicyclic imminium compounds as antitumor agents |
| 12/27/2013 | WO2013192286A1 Iap antagonists |
| 12/27/2013 | WO2013192224A1 Synergistic combination for treating a cancer |
| 12/27/2013 | WO2013192098A1 SUBSTITUTED PYRIDINE SPLEEN TYROSINE KINASE (Syk) INHIBITORS |
| 12/27/2013 | WO2013192088A1 SUBSTITUTED DIAZINE AND TRIAZINE SPLEEN TYROSINE KINASE (Syk) INHIBITORS |
| 12/27/2013 | WO2013191965A1 Reversible covalent pyrrolo- or pyrazolopyrimidines useful for the treatment cancer and autoimmune diseases |
| 12/27/2013 | WO2013191242A1 Test method and treatment means for small cell lung cancer having poor prognosis |
| 12/27/2013 | WO2013191225A1 Mucosal immunity-stimulating agent, and oral pharmaceutical composition for treating hpv infection |
| 12/27/2013 | WO2013190555A1 Lsr antibodies, and uses thereof for treatment of cancer |
| 12/27/2013 | WO2013190355A1 Oxathiazine derivatives as antibacterial and anticancer agents |
| 12/27/2013 | WO2013190320A1 Imidazopyridines as inhibitors of aurora kinase and/or flt3 |
| 12/27/2013 | WO2013190319A1 Pharmaceutically active compounds |
| 12/27/2013 | WO2013190292A2 Novel process for preparation of antibody conjugates and novel antibody conjugates |
| 12/27/2013 | WO2013190290A1 An oncolytic herpes simplex virus for use in the treatment of cancer |
| 12/27/2013 | WO2013190273A1 Therapeutic composition |
| 12/27/2013 | WO2013189910A1 Multicomponent crystals comprising imatinib mesilate and selected co-crystal formers |
| 12/27/2013 | WO2013189905A1 Pyrrolopyrazone inhibitors of tankyrase |
| 12/27/2013 | WO2013189847A1 Bendamustine derivatives and related compounds, and medical use thereof cancer therapy |
| 12/27/2013 | WO2013189841A1 New bicyclic thiophenylamide compounds |
| 12/27/2013 | WO2013189663A1 Conjugate of a photosensitiser and chitosan and uses thereof |
| 12/27/2013 | WO2013189309A1 Microparticle comprising functional microrna/sirna and application thereof |
| 12/27/2013 | WO2013189287A1 Use of interferon in treatment/prevention of tumors resistant to conventional anti-tumor therapy |
| 12/27/2013 | WO2013189266A1 Compound of camptothecin and preparation and use thereof |
| 12/27/2013 | WO2013189241A1 Pyrimidine diamine derivative, preparation method therefor, and pharmaceutical uses thereof |
| 12/27/2013 | WO2013189237A1 Andrographolide analogue and application of andrographolide analogue to treatment |
| 12/27/2013 | WO2013189121A1 Deuterated benzopyran compound and application thereof |
| 12/27/2013 | WO2013157889A9 Use of a novel aminopyridine derivative to prevent or treat cancer |
| 12/27/2013 | WO2013124807A3 Oligonucleotides for modulating gene expression and uses thereof |
| 12/27/2013 | CA2877573A1 Antigen binding proteins that bind c-met |
| 12/27/2013 | CA2877533A1 Novel vista-ig constructs and the use of vista-ig for treatment of autoimmune, allergic and inflammatory disorders |
| 12/27/2013 | CA2877473A1 Imidazo bicyclic imminium compounds as antitumor agents |
| 12/27/2013 | CA2877089A1 Novel 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one and this1,2,3,4-tetrahydropyrimido{1,2-a}pyrimidin-6-one derivatives comprising a substituted morpholine, preparation thereof and pharmaceutical use thereof |
| 12/27/2013 | CA2877030A1 Multicomponent crystals comprising imatinib mesilate and selected co-crystal formers |
| 12/27/2013 | CA2876957A1 Compounds with (1e, 6e)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disubstituted-hepta-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof |
| 12/27/2013 | CA2876945A1 1,2,4-triazine-6-carboxamide kinase inhibitors |
| 12/27/2013 | CA2876904A1 Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof |
| 12/27/2013 | CA2876365A1 Novel process for preparation of antibody conjugates and novel antibody conjugates |
| 12/27/2013 | CA2876357A1 Pharmaceutically active compounds |
| 12/27/2013 | CA2876001A1 Salt crystals |
| 12/27/2013 | CA2875944A1 Novel anti-cancer compounds |
| 12/27/2013 | CA2875721A1 Deuterated benzopyran compound and application thereof |
| 12/27/2013 | CA2875543A1 Antigen binding proteins that bind igf1r |
| 12/27/2013 | CA2875455A1 Bendamustine derivatives and related compounds, and medical use thereof cancer therapy |
| 12/27/2013 | CA2875389A1 1-[m-carboxamido(hetero)aryl-methyl]-heterocyclyl-carboxamide derivatives |
| 12/27/2013 | CA2874897A1 Method and composition for alleviating tumor symptoms |
| 12/27/2013 | CA2848291A1 Lsr antibodies, and uses thereof for treatment of cancer |
| 12/26/2013 | US20130347146 Gntiii expression in plants |
| 12/26/2013 | US20130345180 2,4- diaminopyrimidine derivatives |
| 12/26/2013 | US20130344031 Substituted pyrrolo-pyrazole derivatives as kinase inhibitors |
| 12/25/2013 | EP2676953A1 Hemifumarate Salt and Medical Indications |
| 12/25/2013 | EP2676670A1 Adiponectin production promoter, and medicinal composition, food, drink and feed containing adiponectin production promoter |
| 12/25/2013 | EP2676664A1 Potentiator of antitumor activity of chemotherapeutic agent |
| 12/25/2013 | EP2675826A1 Antibody against the csf-1r |
| 12/25/2013 | EP2675802A1 2-anilino nicotinyl linked 2-amino benzothiazole conjugates and process for the preparation thereof |
| 12/25/2013 | EP2675794A1 Selective fak inhibitors |
| 12/25/2013 | EP2675793A1 Fak inhibitors |
| 12/25/2013 | EP2675788A1 Substituted 3-(biphenyl-3-yl)-8,8-difluoro-4-hydroxy-1-azaspiro[4.5]dec-3-en-2-ones for therapy |
| 12/25/2013 | EP2675483A2 Enhanced therapeutic usage of a purine nucleoside phosphorylase or nucleoside hydrolase prodrug related applications |
| 12/25/2013 | EP2675482A2 Carrier peptides for cell delivery |